- Home
- MIRA vs ECOR Comparison
MIRA vs ECOR Comparison
Compare MIRA & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRA | ECOR |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7M | 39.6M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MIRA | ECOR |
|---|---|---|
| Price | $1.50 | $4.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $25.50 |
| AVG Volume (30 Days) | ★ 251.1K | 41.5K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,835,000.00 |
| Revenue This Year | N/A | $28.61 |
| Revenue Next Year | N/A | $41.21 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 27.90 |
| 52 Week Low | $0.73 | $4.16 |
| 52 Week High | $2.45 | $19.49 |
Technical Indicators
Market Signals| Indicator | MIRA | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 50.32 | 41.80 |
| Support Level | $1.52 | $4.41 |
| Resistance Level | $1.69 | $5.00 |
| Average True Range (ATR) | 0.08 | 0.26 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 24.00 | 21.54 |
Price Performance
Historical ComparisonAbout MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.